/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Edesa Biotech Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.74 -0.0042(-0.42%) EDSA at 04 Dec 2025 04:30 PM Biotechnology
Lowest Today 1.7
Highest Today 1.725
Today’s Open 1.7
Prev. Close 1.73
52 Week High 4.49
52 Week Low 1.55
Day’s Range: Low 1.7 High 1.725
52-Week Range: Low 1.55 High 4.49
1 day return -
1 Week return +0.58
1 month return +1.18
3 month return -32.41
6 month return -10.0
1 year return -26.6
3 year return -75.69
5 year return -95.03
10 year return -

Institutional Holdings

Rubric Capital Management LP 9.77

Velan Capital Investment Management LP 9.77

Nantahala Capital Management, LLC 8.88

Commonwealth Equity Services Inc 0.50

Vanguard Institutional Extnd Mkt Idx Tr 0.46

Geode Capital Management, LLC 0.40

Citadel Advisors Llc 0.33

Fidelity Extended Market Index 0.24

Vanguard Group Inc 0.23

Spartan Extended Market Index Pool F 0.07

Fidelity Series Total Market Index 0.06

Tower Research Capital LLC 0.03

Northern Trust Extended Eq Market Idx 0.03

NT Ext Equity Mkt Idx Fd - L 0.03

Royal Bank of Canada 0.03

Fidelity Nasdaq Composite Index 0.02

NT Ext Equity Mkt Idx Fd - NL 0.02

Fidelity Total Market Index 0.02

Spartan Total Market Index Pool G 0.01

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.01

UBS Group AG 0.01

Morgan Stanley - Brokerage Accounts 0.01

State St US Extended Mkt Indx NL Cl C 0.01

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.01

NT Ext Eq Mkt Indx Fd DC Lend T3 0.01

SSgA U.S. Total Market Index Strategy 0.00

Efficient Wealth Management LLC 0.00

State St US Ttl Mkt Indx NL Cl A 0.00

Vanguard U.S. Eq Idx £ Acc 0.00

TD Waterhouse Canada Inc 0.00

Fifth Third Bancorp 0.00

Bank of America Corp 0.00

Northern Trust Wilshire 5000 0.00

Global Retirement Partners, LLC. 0.00

Fidelity U.S. Equity Index Ins Trust 0.00

AllSquare Wealth Management LLC 0.00

Crédit Agricole S.A. 0.00

Dogwood Wealth Management LLC 0.00

LRI Investments, LLC 0.00

Market Status

Strong Buy: 1

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 12.70 M

PB Ratio 2.6171

PE Ratio 0.0

Enterprise Value 11.83 M

Total Assets 3.81 M

Volume 6349

Company Financials

Annual Revenue FY24:0 0.0M, FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:328801 0.3M

Annual Profit FY24:null 0.0M, FY23:null 0.0M, FY22:null 0.0M, FY21:0 0.0M, FY20:311200 0.3M

Annual Net worth FY24:-6170045 -6.2M, FY23:-8374415 -8.4M, FY22:-17548924 -17.5M, FY21:-13343150 -13.3M, FY20:-6364230 -6.4M

Quarterly Revenue Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q4/2024:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q2/2025:-25787 -0.0M, Q1/2025:-24509 -0.0M, Q4/2024:null 0.0M, Q3/2024:null 0.0M, Q2/2024:-51415 -0.1M

Quarterly Net worth Q2/2025:-1749464 -1.7M, Q1/2025:-1590448 -1.6M, Q4/2024:-1617253 -1.6M, Q3/2024:-962051 -1.0M, Q2/2024:-1668212 -1.7M

Fund house & investment objective

Company Information Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Organisation Biotechnology

Employees 16

Industry Biotechnology

CEO Dr. Pardeep Nijhawan FRCPC, M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow